NexTel Medical Corp. Executes Letter of Intent to Acquire 100% of Xycota Biosciences, LLC
Rhea-AI Summary
NexTel Medical (OTC: MAJI) has executed a definitive Letter of Intent to acquire 100% of Xycota Biosciences, a preclinical biotech developing non-psychoactive, exosome-delivered therapeutics to repair brain circuitry and restore synaptic connectivity in severe neurodegenerative diseases.
Xycota’s lead candidate, XYCO-01, uses proprietary fungal-derived exosome delivery to upregulate the BDNF‑TrkB neuroplasticity pathway while avoiding first-pass liver metabolism and hallucinogenic receptor activation. Xycota has applied to the FDA for Orphan Drug Designation for XYCO-01 in Frontotemporal Dementia, with issuance expected by the company. The platform is led by co-founder and CSO Dr. Marvin S. Hausman, who is credited with over 50 years of CNS drug development experience and six successful FDA NDAs, and is positioned for follow-on indications including ALS, mild traumatic brain injury and broader neurodegenerative conditions.
Positive
- LOI to acquire 100% of Xycota Biosciences expands NexTel’s neurodegeneration pipeline
- Lead asset XYCO-01 targets BDNF-TrkB neuroplasticity via exosome delivery in Frontotemporal Dementia
- Orphan Drug Designation application filed with FDA for XYCO-01 in FTD, with potential exclusivity and tax benefits
- Experienced scientific leadership via CSO Dr. Marvin Hausman, credited with 6 prior FDA NDAs
Negative
- Transaction at LOI stage only, with no disclosed closing terms, timing, or financial consideration
- Xycota is preclinical, with no approved products or late-stage clinical data disclosed
- Orphan Drug Designation for XYCO-01 is pending and not yet granted by the FDA
News Market Reaction – MAJI
In the Aug 5 session, MAJI gained 2.25%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Strategic Acquisition Positions NexTel at the Forefront of Precision Neuro-Restoration with Xycota's Breakthrough Exosome-Delivered Brain Circuitry Repair Platform and Pending FDA Orphan Drug Designation
ORLANDO, FL / ACCESS Newswire / August 5, 2026 / NexTel Medical Corp. (f/k/a Exousia Pro, Inc.) (OTCID:MAJI), today announced that it has executed a definitive Letter of Intent (LOI) to acquire
Xycota is advancing a transformative biological interface designed to physically repair damaged neural networks in catastrophic neurodegenerative diseases. By utilizing proprietary fungal-derived exosome delivery systems, Xycota's lead candidate, XYCO-01, directly upregulates the BDNF-TrkB neuroplasticity signaling pathway while bypassing first-pass liver metabolism and hallucinogenic receptor activation. This paradigm-shifting approach decouples therapeutic neural restoration from psychedelic side effects, establishing a standardized, controllable mechanism for structural brain repair.
Key Regulatory & Growth Catalyst: Pending FDA Orphan Drug Designation
Xycota has formally applied for Orphan Drug Designation (ODD) with the U.S. Food and Drug Administration (FDA) for XYCO-01 in its primary indication, Frontotemporal Dementia (FTD). Official issuance of the ODD status is expected shortly. Upon designation and approval, ODD status provides seven years of U.S. market exclusivity, tax credits for qualified clinical testing, and regulatory fee exemptions, greatly accelerating the clinical and commercial development roadmap.
Cutting-Edge Scientific Foundation & Platform Synergy
Xycota's platform is anchored by peer-reviewed mechanistic evidence published in the Nature Portfolio journal Neuropsychopharmacology (Trezza, Hausman, et al., 2026 Psilocybin improves novel object recognition... through the modulation of the BDNF/TrkB signaling pathway, demonstrating that synaptic restoration and cognitive improvement can be achieved by modulating intrinsic BDNF/TrkB growth pathways. Xycota's pipeline is led by Co-Founder & Chief Scientific Officer Dr. Marvin S. Hausman, MD, who brings over 50 years of CNS drug development experience, 6 successful FDA NDAs, and a proven track record of commercial exits.
Following the initial lead indication in Frontotemporal Dementia, the platform offers rapid expansion into Amyotrophic Lateral Sclerosis (ALS), mild traumatic brain injury (mTBI), and broader neurodegenerative conditions.
"Executing this LOI to acquire
About Xycota Biosciences, LLC
Xycota Biosciences, LLC is a precision biotechnology company engineering exosome-delivered neuroplasticity therapeutics to repair brain circuitry. Anchored by peer-reviewed science and institutional leadership, Xycota is building a scalable translational platform targeting FTD, ALS, and neurodegenerative disorders. For more information, visit https://xycota.com/ and connect on LinkedIn at https://www.linkedin.com/company/xycota-biosciences.
About NexTel Medical Corp.
NexTel Medical Corp. is a medical technology and biotechnology enterprise focused on acquiring, integrating, and commercializing high-impact medical platforms, novel therapeutic delivery technologies, and healthcare innovations.
Media & Investor Contacts:
NexTel Medical Corp.
Investor Relations & Corporate Communications
Email: ir@nextelmedical.com
Website: www.nextelmedical.com
Xycota Biosciences, LLC
Brad Listermann, President & Co-Founder
Email: info@xycota.com
Website: https://xycota.com/
SOURCE: NexTel Medical Corp
View the original press release on ACCESS Newswire